Prognosis of hepatocellular carcinoma expressing cytokeratin 19: Comparison with other liver cancers

doi:10.3748/wjg.v18.i34.4751

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 34

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5405)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

493

HTML

4557

Figures (1-2)

228

Tables (1-2)

127

Sum=5405

Sep 14, 2012 (publication date) through Apr 19, 2024

Times Cited of This Article

Times Cited (54)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Sep 14, 2012; 18(34): 4751-4757
Published online Sep 14, 2012. doi: 10.3748/wjg.v18.i34.4751

Table 1 Clinical characteristics of patients and treatment modality of recurrent with primary liver cancer n (%)

	CK19^- HCC (n = 49)	CK19⁺ HCC (n = 21)	cHCC-CC (n = 22)	ICC(n = 19)	P value
Age (yr)					0.43
< 45	11 (22.4)	4 (19.0)	4 (18.2)	1 (5.3)
≥ 45	38 (77.6)	17 (81.0)	18 (81.8)	18 (94.7)
Gender					0.014^a
Male	41 (83.7)	14 (66.7)	18 (81.8)	9 (47.4)
Female	8 (16.3)	7 (33.3)	4 (18.2)	10 (52.6)
Underlying liver disease					0.004^a
None	0 (0.0)	0 (0.0)	3 (13.6)	12 (63.2)
HBV	38 (79.2)	18 (85.7)	17 (77.3)	2 (10.5)
HCV	4 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)
Others	6 (12.5)	3 (14.3)	2 (9.1)	5 (26.3)
Cirrhosis					0.024^a
No	22 (44.9)	10 (47.6)	10 (45.5)	16 (84.2)
Yes	27 (55.1)	11 (52.4)	12 (54.5)	3 (15.8)
Tumor number					0.313
Single	41 (83.7)	17 (81.0)	16 (72.7)	18 (94.7)
Multiple	8 (16.3)	4 (19.0)	6 (27.3)	1 (5.3)
Satellite nodule					0.063
Absent	43 (87.8)	19 (90.5)	15 (68.2)	18 (94.7)
Present	6 (12.2)	2 (9.5)	7 (31.8)	1 (5.3)
Microvascular invasion					0.836
Absent	21 (42.9)	10 (47.6)	11 (55.0)	9 (47.4)
Present	28 (57.1)	11 (52.4)	9 (45.0)	10 (52.6)
Macrovascular invasion					0.119
Absent	45 (91.8)	17 (81.0)	19 (95.0)	14 (73.7)
Present	4 (8.2)	4 (19.0)	1 (5.0)	5 (26.3)
Lymph node metastasis					0.086
Absent	47 (95.9)	20 (95.5)	21 (95.5)	15 (78.9)
Present	2 (4.1)	1 (4.8)	1 (4.5)	4 (21.1)
Distant metastasis					0.521
Absent	46 (93.9)	21 (100)	21 (95.5)	17 (89.5)
Present	3 (6.1)	0 (0.0)	1 (4.5)	2 (10.5)
Differentiation					0.301
E1, E2 or well, moderate	15 (30.6)	7 (33.3)	9 (47.4)	9 (52.9)
E3, E4 or poorly	34 (69.4)	14 (66.7)	10 (52.6)	8 (47.1)
Treatment modality
Number of patience with recurrence	19/49 (38.8)	12/21 (57.1)	15/22 (68.2)	11/19 (57.9)
Conservative treatment	2/19 (10.5)	1/12 (8.3)	3/15 (20.0)	8/11 (72.7)
Transarterial chemoembolization	15/19 (78.9)	11/12 (91.7)	12/15 (80.0)	0/11 (0.0)
Systemic chemotherapy	0/19 (0.0)	0/12 (0.0)	0/15 (0.0)	2/11 (3.5)
Others	2/19 (10.5)	0/12 (0.0)	0/15 (0.0)	3/11 (5.3)

^aP < 0.05 among 4 groups. CK19^- HCC: Cytokeratin 19 negative hepatocellular carcinoma; CK19⁺ HCC: Cytokeratin 19 positive hepatocellular carcinoma; cHCC-CC: Combined hepatocellular carcinoma and cholangiocarcinoma; ICC: Intrahepatic cholangiocarcinoma; HBV: Hepatitis B virus; HCV: Hepatitis C virus.

Citation: Lee JI, Lee JW, Kim JM, Kim JK, Chung HJ, Kim YS. Prognosis of hepatocellular carcinoma expressing cytokeratin 19: Comparison with other liver cancers. World J Gastroenterol 2012; 18(34): 4751-4757
URL: https://www.wjgnet.com/1007-9327/full/v18/i34/4751.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i34.4751